New hope drug enters human testing for Tough-to-Treat cancers
NCT ID NCT07222969
Summary
This early-stage clinical trial is testing a new drug called VIB305 in people with advanced solid tumors that have stopped responding to standard treatments. The study aims to find the safest and most effective dose while checking if the drug can shrink tumors. It will enroll about 146 adults whose cancer has spread and who have few other options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
Contact
-
Sunshine Coast University Private Hospital
RECRUITINGSunshine Coast, Australia
Contact
Conditions
Explore the condition pages connected to this study.